Viking accelerates development of obesity drug that could rival Wegovy, Zepbound

Taking stock of the drug industry, from the lab to the medicine chest

July 25, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mark Lennihan/AP STAT+ | Viking accelerates development of obesity drug that could rival Wegovy, Zepbound The San Diego-based biotech said Wednesday during an earnings call that it's moving directly to a Phase 3 study of its drug. By Elaine Chen STAT+ | Roche CEO explains the company's weight loss drug strategy in crowded market Roche CEO Thomas Schinecker says drugs under development include weight loss pills and maintenance treatments after people lose weight with an injectable. By Andrew Joseph Opinion: Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it There's an overlooked innovation in the FDA's non-approval of MDMA for PTSD — combining a medication and a psychotherapy as a bundled intervention. By Thomas R. Insel STAT+ | How UnitedHealth harnesses its physician empire to squeeze profits out of patients The insurer UnitedHealth is using its unrivaled physician empire to enrich itself by milking Medicare Advantage. By Bob Herman, Tara Bannow, Casey Ross, and Lizzy Lawrence

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser